Lou Weiyang, Liu Jingxing, Ding Bisha, Xu Liang, Fan Weimin
Program of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China,
Key Laboratory of Organ Transplantation, Zhejiang Province, Hangzhou 310003, China,
Cancer Manag Res. 2018 Oct 23;10:4747-4757. doi: 10.2147/CMAR.S172722. eCollection 2018.
Neoadjuvant chemotherapy (NAC) is an effective therapeutic regimen for patients with breast cancer. However, some individuals cannot benefit from NAC because of drug resistance. To date, valid strategies about enhancing sensitivity of breast cancer to NAC are still scarce. miRNAs have been reported to proverbially be involved in the onset and development of malignancies including drug resistance.
GSE73736 was downloaded from the GEO database. Student's -test was conducted to acquire differentially expressed-miRNAs (DE-miRNAs). Potential target genes of DE-miRNAs were predicted by miRTarBase. Gene Ontology annotation and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses for these target genes were performed by database for annotation, visualization, and integrated discovery. Protein-protein interaction network was constructed by STRING database and visualized through Cytoscape software. The hub target gene-miRNA network was also established by Cytoscape software. Next, the expression of potential functional miRNAs in breast cancer cell lines and tissues was determined. Finally, the roles of miR-3617-3p, miR-3136-3p, and miR-520b in modulating breast cancer chemoresistance were further examined.
A total of 123 DE-miRNAs were identified, including 60 upregulated miRNAs and 63 downregulated miRNAs in the chemoresistant breast cancer group when compared with the chemosensitive group. Six hundred and seventeen and 1,146 potential target genes for the top 10 most upregulated and downregulated miRNAs were predicted, respectively. Enrichment analyses revealed that these target genes were enriched in some cancer-associated or chemo-resistance-associated pathways, such as MAPK signaling pathway, wnt signaling pathway, and p53 signaling pathway. and were identified as hub genes in the protein-protein interaction network. The top 25 hub genes were potentially regulated by 16 DE-miRNAs, among which miR-3617-3p and miR-3136-3p were commonly upregulated, whereas miR-520b was downregulated in two chemoresistant breast cancer cells compared with chemosensitive cell. By analyzing TCGA data, we found that expression of miR-3136-3p and miR-520b was increased and decreased in breast cancer tissues, respectively. Moreover, functional experiments demonstrated that miR-3136-3p and miR-3617-3p could reduce chemosensitivity of breast cancer, whereas miR-520b could reverse chemoresistance.
The present study, based on bioinformatics analysis and experimental validation, brings to light novel mechanisms of breast cancer NAC resistance.
新辅助化疗(NAC)是乳腺癌患者有效的治疗方案。然而,一些个体因耐药性无法从NAC中获益。迄今为止,关于提高乳腺癌对NAC敏感性的有效策略仍然匮乏。据报道,miRNA普遍参与包括耐药性在内的恶性肿瘤的发生和发展。
从GEO数据库下载GSE73736。进行学生t检验以获得差异表达的miRNA(DE-miRNA)。通过miRTarBase预测DE-miRNA的潜在靶基因。通过注释、可视化和综合发现数据库对这些靶基因进行基因本体注释和京都基因与基因组百科全书通路富集分析。利用STRING数据库构建蛋白质-蛋白质相互作用网络,并通过Cytoscape软件进行可视化。枢纽靶基因-miRNA网络也通过Cytoscape软件建立。接下来,测定乳腺癌细胞系和组织中潜在功能性miRNA的表达。最后,进一步研究miR-3617-3p、miR-3136-3p和miR-520b在调节乳腺癌化疗耐药性中的作用。
共鉴定出123个DE-miRNA,与化疗敏感组相比,化疗耐药乳腺癌组中有60个miRNA上调,63个miRNA下调。分别预测了上调和下调最显著的前10个miRNA的617个和1146个潜在靶基因。富集分析表明,这些靶基因富集于一些与癌症相关或化疗耐药相关的通路,如MAPK信号通路、Wnt信号通路和p53信号通路。 和 在蛋白质-蛋白质相互作用网络中被鉴定为枢纽基因。前25个枢纽基因可能受16个DE-miRNA调控,其中miR-3617-3p和miR-3136-3p通常上调,而与化疗敏感细胞相比,miR-520b在两种化疗耐药乳腺癌细胞中下调。通过分析TCGA数据,我们发现miR-3136-3p和miR-520b在乳腺癌组织中的表达分别升高和降低。此外,功能实验表明,miR-3136-3p和miR-3617-3p可降低乳腺癌的化疗敏感性,而miR-520b可逆转化疗耐药性。
本研究基于生物信息学分析和实验验证,揭示了乳腺癌NAC耐药的新机制。